SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Samrat Pharmachem informs about newspaper advertisement

03 Jun 2024 Evaluate
As per requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, Samrat Pharmachem has informed that it enclosed copies of advertisement of the Extract of the Standalone Audited Financial Results for the year ended March 31, 2024 as published in newspapers pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The advertisement is published in the Baroda Edition of ‘Indian Express’, English Edition & ‘Vadodara Samachar’, Gujarati Edition on Saturday, June 1, 2024.

The above information is a part of company’s filings submitted to BSE.

Samrat Pharmachem Share Price

213.00 -5.90 (-2.70%)
24-Apr-2026 11:52 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1624.65
Dr. Reddys Lab 1320.00
Cipla 1285.60
Zydus Lifesciences 929.65
Lupin 2275.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×